Differences in cytochrome P450 and nuclear receptor mRNA levels in liver and small intestines between SD and DA rats

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 3, 2008, Pages 196-206

  Kawase, Atsushi ^a   Fujii, Akiyuki ^a   Negoro, Makiko ^a   Akai, Ryosuke ^a   Ishikubo, Miki ^a   Komura, Hiroshi ^a   Iwaki, Masahiro ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Cytochrome P450; DA rat; Nuclear receptor; SD rat; Strain difference

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; C REACTIVE PROTEIN; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 1A1; CYTOCHROME P450 2A; CYTOCHROME P450 2B; CYTOCHROME P450 2B1; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 2E; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; CELL RECEPTOR; ISOPROTEIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; MALE; MICROSOME; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; RAT STRAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; STRAIN DIFFERENCE; ANIMAL; ANTIBODY SPECIFICITY; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULAR GENETICS; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT;

ANIMALS; BASE SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; INTESTINE, SMALL; LIVER; MALE; MICROSOMES; MOLECULAR SEQUENCE DATA; ORGAN SPECIFICITY; PROTEIN ISOFORMS; RATS; RATS, INBRED STRAINS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SPECIES SPECIFICITY;

EID: 48849089434     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.196     Document Type: Article

References (52)

1. Kaminsky, L. S. and Fasco, M. J.: Small intestinal cytochromes P450. Crit. Rev. Toxicol., 21: 407-422 (1991).
2. Lin, J. H., Chiba, M. and Baillie, T. A.: Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev., 51: 135-158 (1999).
3. Doherty, M. M. and Charman, W. N.: The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet., 41: 235-253 (2002).
4. Ding, X. and Kaminsky, L. S.: Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol., 43: 149-173 (2003).
5. Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D. and Thummel, K. E.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther., 283: 1552-1562 (1997).
6. Strassburg, C. P., Kneip, S., Topp, J., Obermayer-Straub, P., Barut, A., Tukey, R. H. and Manns, M. P.: Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J. Biol. Chem., 275: 36164-36171 (2000).
7. Zhang, Q. Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J. and Kaminsky, L. S.: Characterization of human small intestinal cytochromes P-450. Drug. Metab. Dispos., 27: 804-809 (1999).
8. Fasco,M. J., Silkworth, J. B., Dunbar, D. A. and Kaminsky, L. S.: Rat small intestinal cytochromes P450 probed by warfarin metabolism. Mol. Pharmacol., 43: 226-233 (1993).
9. Zhang, Q. Y., Wikoff, J., Dunbar, D. and Kaminsky, L.: Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug. Metab. Dispos., 24: 322-328 (1996).
10. Yamamoto, Y., Tasaki, T., Nakamura, A., Iwata, H., Kazusaka, A., Gonzalez, F. J. and Fujita, S.: Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics, 8: 73-82 (1998).
11. Kahn, G. C., Rubenfield, M., Davies, D. S., Murray, S. and Boobis, A. R.: Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat. Drug. Metab. Dispos., 13: 510-516 (1985).
12. Suzuki, T., Narimatsu, S., Fujita, S., Masubuchi, Y. and Umeda, S.: Impairment of bunitrolol 4-hydroxylase activity in liver microsomes of dark agouti rats. Biochem. Pharmacol., 42: 2241-2244 (1991).
13. Narimatsu, S., Tachibana, M., Masubuchi, Y., Imaoka, S., Funae, Y. and Suzuki, T.: Cytochrome P450 isozymes involved in aromatic hydroxylation and side-chain N-desisopropylation of alprenolol in rat liver microsomes. Biol. Pharm. Bull., 18: 1060-1065 (1995).
14. Barham, H. M., Lennard, M. S. and Tucker, G. T.: An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochem. Pharmacol., 47: 1295-1307 (1994).
15. Saito, K., Sakai, N., Kim, H. S., Ishizuka, M., Kazusaka, A. and Fujita, S.: Strain differences in diazepam metabolism at its three metabolic sites in sprague-dawley, brown norway, dark agouti, and wistar strain rats. Drug Metab. Dispos., 32: 959-965 (2004).
16. Kajbaf, M., Jahanshahi, M., Lamb, J. H., Gorrod, J. W. and Naylor, S.: Bioanalytical applications of tandem mass spectrometry in the in vitro metabolism of the anticholinergic drug cimetropium bromide to detect differences in species metabolism. Xenobiotica., 22: 641-655 (1992).
17. Garcia-Agundez, J. A. and Benitez, J.: Sex and age-related differences in aminopyrine N-demethylase activity in DA- and Wistarstrain rat liver microsomes. Effect of ovariectomy.: Xenobiotica., 21: 755-762 (1991).
18. Smith, A. J. and Chipman, J. K.: Inter-individual variation in the mutagenic activation of 2-acetylaminofluorene by human liver in relation to animal metabolic models. Mutagenesis., 3: 323-328 (1988).
19. Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterstrom, R. H., Perlmann, T. and Lehmann, J. M.: An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell, 92: 73-82 (1998).
20. Honkakoski, P., Zelko, I., Sueyoshi, T. and Negishi, M.: The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol. Cell Biol., 18: 5652-5658 (1998).
21. Waxman, D. J.: P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem. Biophys., 369: 11-23 (1999).
22. Squires, E. J., Sueyoshi, T. and Negishi, M.: Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J. Biol. Chem., 279: 49307-49314 (2004).
23. Kobayashi, K., Sueyoshi, T., Inoue, K., Moore, R. and Negishi, M.: Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Mol. Pharmacol., 64: 1069-1075 (2003).
24. Rastinejad, F.: Retinoid X receptor and its partners in the nuclear receptor family. Curr. Opin. Struct. Biol., 11: 33-38 (2001).
25. Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., Roberts, R. A. and Fenner-Crisp, P. A.: PPAR-alpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol., 33: 655-780 (2003).
26. Nebert, D. W., Dalton, T. P., Okey, A. B. and Gonzalez, F. J.: Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem., 279: 23847-23850 (2004).
27. Chen, D., Lepar, G. and Kemper, B.: A transcriptional regulatory element common to a large family of hepatic cytochrome P450 genes is a functional binding site of the orphan receptor HNF-4. J Biol Chem., 18: 5420-5427 (1994).
28. Akiyama, T. E. and Gonzalez, F. J.: Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. Biochim. Biophys. Acta., 1619: 223-234 (2003).
29. Peng, F. C., Jian, W. C. and Edwards, R. J.: Profile of territrem metabolism and cytochrome P-450 3A expression in liver microsomes from Wistar rats of both genders as a function of age. J. Toxicol. Environ. Health A., 12: 1871-1888 (2005).
30. Komura, H. and Iwaki, M.: Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: the female DA rat is not always an animal model for poor metabolizers of CYP2D6. J. Pharm. Sci., 94: 397-408 (2005).
31. Komura, H., Yasuda, M., Yoshida, N. H. and Sugiyama, Y.: Species difference in nisoldipine oxidation activity in the small intestine. Drug Metab. Pharmacokin., 17: 427-436 (2002).
32. Matsubara, T., Kim, H. J., Miyata, M., Shimada, M., Nagata, K. and Yamazoe, Y.: Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J. Pharmacol. Exp. Ther., 309: 1282-1290 (2004).
33. Saito, K., Sakai, N., Kim, H. S., Ishizuka, M., Kazusaka, A. and Fujita, S.: Strain differences in diazepam metabolism at its three metabolic sites in sprague-dawley, brown norway, dark agouti, and wistar strain rats. Drug Metab Dispos., 32: 959-965 (2004).
34. Masubuchi, Y., Takahashii, C., Fujio, N., Horie, T., Suzuki, T., Imaoka, S., Funae, Y. and Narimatsu, S.: Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats. Drug Metab. Dispos., 23: 999-1003 (1995).
35. Al-Dabbagh, S. G., Idle, J. R. and Smith, R. L.: Animal modelling of human polymorphic drug oxidation-the metabolism of debrisoquine and phenacetin in rat inbred strains. J. Pharm. Pharmacol., 33: 161-164 (1981).
36. Law, M. Y. and Moody, D. E.: Urinary excretion of amphetamine and 4′-hydroxyamphetamine by Sprague Dawley and dark Agouti rats. Life Sci., 54: 1073-1079 (1994).
37. Law, M. Y. and Moody, D. E.: Urinary excretion of 4-hydroxyamphetamine and amphetamine in male and female Sprague-Dawley and Dark Agouti rats following multiple doses of amphetamine. Toxicol. Lett., 117: 139-144 (2000).
38. Zysset, T., Zeugin, T. and Kupfer, A.: In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochem. Pharmacol., 37: 3155-3160 (1988).
39. Muralidharan, G., Midha, K. K., McKay, G., Hawes, E. M. and Inaba, T.: Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. Xenobiotica, 19: 189-197 (1989).
40. Staack, R. F., Paul, L. D., Springer, D., Kraemer, T. and Maurer, H. H.: Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem. Pharmacol., 67: 235-244 (2004).
41. Morgan, E. T., Sewer, M. B., Iber, H., Gonzalez, F. J., Lee, Y. H., Tukey, R. H., Okino, S., Vu, T., Chen, Y. H., Sidhu, J. S. and Omiecinski, C. J.: Physiological and pathophysiological regulation of cytochrome P450. Drug Metab. Dispos., 26: 1232-1240 (1998).
42. Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D. M., Gillies, B. S. and Thummel, K. E.: First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther., 60: 14-24 (1996).
43. Thummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D. and Wilkinson, G. R.: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther., 59: 491-502 (1996).
44. Wandel, C., Bocker, R., Bohrer, H., Browne, A., Rugheimer, E. and Martin, E.: Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br. J. Anaesth., 73: 658-661 (1994).
45. Ghosal, A., Satoh, H., Thomas, P. E., Bush, E. and Moore, D.: Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab. Dispos., 24: 940-947 (1996).
46. Cotreau, M. M., von Moltke, L. L., Beinfeld, M. C. and Greenblatt, D. J.: Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. J. Pharmacol. Toxicol. Methods, 43: 41-54 (2000).
47. Takara, K., Ohnishi, N., Horibe, S. and Yokoyama, T.: Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine. Drug Metab. Dispos., 31: 1235-1239 (2003).
48. Tamura, S., Tokunaga, Y., Ibuki, R., Amidon, G. L., Sezaki, H. and Yamashita, S.: The site-specific transport and metabolism of tacrolimus in rat small intestine. J. Pharmacol. Exp. Ther., 306: 310-316 (2003).
49. Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P. and Negishi, M.: The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem., 274: 6043-6046 (1999).
50. Goodwin, B., Hodgson, E., D'Costa, D. J., Robertson, G. R. and Liddle, C.: Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol., 62: 359-365 (2002).
51. Gerbal-Chaloin, S., Daujat, M., Pascussi, J. M., Pichard-Garcia, L., Vilarem, M. J. and Maurel, P.: Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem., 277: 209-217 (2002).
52. Kassam, A., Winrow, C. J., Fernandez-Rachubinski, F., Capone, J. P. and Rachubinski, R. A.: The peroxisome proliferator response element of the gene encoding the peroxisomal beta-oxidation enzyme enoyl-CoA hydratase/ 3-hydroxyacyl-CoA dehydrogenase is a target for constitutive androstane receptor beta/9-cis-retinoic acid receptor-mediated transactivation. J. Biol. Chem., 275: 4345-4350 (2000).